Live-cell imaging of cell-to-cell variability in caspase-8 FRET reporter activity and cell fate trajectory modeling - Dataset (ID:20232)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | Protein | Protein Concentration | Protein Conc Unit | Antibody Name | Antibody Concentration | Antibody Conc Unit | 2nd Antibody Name | 2nd Antibody Concentration | 2nd Antibody Conc Unit | Replicate | Mean log10(k) (a.u.) | Mean tau (min) | Surviving Fraction | Classification Accuracy (theta_T) | Classification Accuracy (fate boundary) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HeLa ICRP | Mapatumumab | 2.5 | nM | anti-Fc | 2.5 | nM | 2 | -5.14 | 181.8431 | 0.494 | 0.90000 | 0.78824 | ||||||
| HeLa ICRP | Mapatumumab | 2.5 | nM | anti-Fc | 2.5 | nM | 1 | -5.02 | 168.6104 | 0.582 | 0.83117 | 0.71688 | ||||||
| HeLa ICRP | Mapatumumab | 5.0 | nM | anti-Fc | 5.0 | nM | 3 | -4.94 | 145.1482 | 0.550 | 0.82210 | 0.67925 | ||||||
| HeLa ICRP | Mapatumumab | 5.0 | nM | anti-Fc | 5.0 | nM | 2 | -4.93 | 153.1692 | 0.347 | 0.89079 | 0.76445 | ||||||
| HeLa ICRP | Mapatumumab | 5.0 | nM | anti-Fc | 5.0 | nM | 1 | -4.80 | 134.6580 | 0.476 | 0.71010 | 0.61238 | ||||||
| HeLa ICRP | Bortezomib | 100 | nM | Mapatumumab | 10.0 | nM | anti-Fc | 10.0 | nM | 2 | -4.93 | 186.2624 | 0.010 | 0.90759 | 0.68812 | |||
| HeLa ICRP | Bortezomib | 100 | nM | Mapatumumab | 10.0 | nM | anti-Fc | 10.0 | nM | 1 | -4.70 | 139.7368 | 0.011 | 0.92026 | 0.78469 | |||
| HeLa ICRP | Mapatumumab | 10.0 | nM | anti-Fc | 10.0 | nM | 1 | -4.49 | 83.0851 | 0.309 | 0.68617 | 0.65691 | ||||||
| HeLa ICRP | Mapatumumab | 10.0 | nM | anti-Fc | 10.0 | nM | 2 | -4.63 | 107.8715 | 0.406 | 0.74559 | 0.66751 | ||||||
| HeLa ICRP | Mapatumumab | 10.0 | nM | anti-Fc | 10.0 | nM | 3 | -4.68 | 110.9162 | 0.288 | 0.84817 | 0.79581 | ||||||
| HeLa ICRP | Apomab | 25.0 | nM | anti-Fc | 25.0 | nM | 4 | -6.12 | 272.4815 | 0.907 | 0.92963 | 0.88889 | ||||||
| HeLa ICRP | Bortezomib | 100 | nM | Apomab | 25.0 | ng/ml | anti-Fc | 25.0 | ng/ml | 2 | -5.36 | 315.9300 | 0.077 | 0.87923 | 0.49275 | |||
| HeLa ICRP | Apomab | 25.0 | nM | anti-Fc | 25.0 | nM | 2 | -5.70 | 239.2890 | 0.839 | 0.94037 | 0.83028 | ||||||
| HeLa ICRP | Apomab | 25.0 | nM | anti-Fc | 25.0 | nM | 3 | -6.52 | 286.1860 | 0.876 | 0.88410 | 0.86523 | ||||||
| HeLa ICRP | Bortezomib | 100 | nM | Apomab | 25.0 | ng/ml | anti-Fc | 25.0 | ng/ml | 3 | -5.87 | 409.3750 | 0.568 | 0.88750 | 0.68250 | |||
| HeLa ICRP | Bortezomib | 100 | nM | Apomab | 25.0 | ng/ml | anti-Fc | 25.0 | ng/ml | 4 | -5.56 | 395.2990 | 0.163 | 0.92691 | 0.51163 | |||
| HeLa ICRP | Apomab | 25.0 | nM | anti-Fc | 25.0 | nM | 5 | -6.31 | 302.5813 | 0.872 | 0.90672 | 0.84816 | ||||||
| HeLa ICRP | Mapatumumab | 25.0 | nM | anti-Fc | 25.0 | nM | 1 | -4.50 | 85.1585 | 0.268 | 0.73592 | 0.70775 | ||||||
| HeLa ICRP | Mapatumumab | 25.0 | nM | anti-Fc | 25.0 | nM | 2 | -4.55 | 92.1239 | 0.381 | 0.66372 | 0.64307 | ||||||
| HeLa ICRP | Apomab | 25.0 | nM | anti-Fc | 25.0 | nM | 1 | -5.57 | 236.0268 | 0.848 | 0.90179 | 0.77679 | ||||||
| HeLa ICRP | Mapatumumab | 25.0 | nM | anti-Fc | 25.0 | nM | 3 | -4.54 | 92.8286 | 0.238 | 0.83860 | 0.78369 | ||||||
| HeLa ICRP | Apomab | 25.0 | nM | anti-Fc | 25.0 | nM | 6 | -5.73 | 240.3203 | 0.808 | 0.91922 | 0.84401 | ||||||
| HeLa ICRP | Bortezomib | 100 | nM | Apomab | 25.0 | ng/ml | anti-Fc | 25.0 | ng/ml | 1 | -5.30 | 298.2392 | 0.073 | 0.94086 | 0.48387 | |||
| HeLa ICRP | Bortezomib | 100 | nM | Apomab | 25.0 | ng/ml | anti-Fc | 25.0 | ng/ml | 5 | -5.44 | 331.4063 | 0.076 | 0.91071 | 0.41295 | |||
| HeLa ICRP | Apomab | 50.0 | nM | anti-Fc | 50.0 | nM | 2 | -5.58 | 216.2613 | 0.820 | 0.96396 | 0.81532 |